PROMISE最小风险评分改善疑似CAD症状患者的风险分类
本研究在PROMISE和Dan-NICAD试验中验证PROMISE最小风险评分(PMRS)对>5%至15%验前概率(PTP)疑似冠心病患者的诊断和预后价值。在发现队列中确定PMRS≥34%对应梗阻性CAD患病率≤5%,该阈值在验证队列中将31.9%的患者降级为低PTP组,降级组梗阻性CAD患病率为3.2%。PMRS≥34%与心肌梗死和死亡风险降低无显著关联(HR 0.58, 95%CI 0.29-1.18, P=0.13)。
要点
- 对PTP 5%-15%的疑似CAD患者,PMRS≥34%可降级约三分之一至低风险组。
- 降级组梗阻性CAD患病率仅3.2%,可减少不必要的诊断检查。
- PMRS≥34%与预后改善无显著关联,需结合传统PTP综合评估。
局限性
- 预后验证队列中PMRS≥34%与心肌梗死和死亡风险降低无显著关联(P=0.13)。
- 研究基于两项临床试验的亚队列,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Guidelines for evaluating patients with suspected coronary artery disease (CAD) recommend pretest probability (PTP) estimation but provide no clear recommendations regarding diagnostic testing in patients with >5% to 15% risk of obstructive CAD. The diagnostic and prognostic value of PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) minimal risk score (PMRS) calculation in this patient group is unknown.
OBJECTIVES: This work aims to improve the evaluation of stable patients with suspected CAD by using the PMRS, which identifies patients at minimal risk of CAD and events in patients with >5% to 15% PTP of obstructive CAD.
METHODS: Greater than 5% to 15% PTP patients from 2 large clinical trials were used for subcohort derivation: PROMISE (N = 10,003) and Dan-NICAD (Danish study of Non-Invasive Testing in Coronary Artery Disease) (N = 3,252). First, the PMRS cutoff associated with a prevalence of obstructive CAD ≤5% was determined in the >5% to 15% PTP PROMISE core lab computed tomographic angiography patients (discovery cohort: n = 2,191). This cutoff was validated for obstructive CAD in >5% to 15% PTP Dan-NICAD patients (CAD validation cohort: n = 1,386) and for prognostic impact on death and myocardial infarction in >5% to 15% PTP PROMISE non-core lab computed tomographic angiography patients (prognosis validation cohort: n = 2,753).
RESULTS: In the discovery cohort, a CAD prevalence of ≤5% was found at a PMRS of ≥34%. In the CAD validation cohort, this cutoff down-classified 442 (31.9%) of >5% to 15% PTP patients into the low PTP group (CAD ≤5%); the prevalence of obstructive CAD in down-classified patients was 3.2% compared to 7.1% in non-down-classified patients. A PMRS ≥34% was nonsignificantly associated with a lower risk of myocardial infarction and death in the prognosis validation cohort (HR: 0.58 [95% CI: 0.29-1.18]; P = 0.13).
CONCLUSIONS: For evaluating patients with suspected CAD, a combined use of traditional PTP and the PMRS correctly down-classified one-third of >5% to 15% PTP patients into a group with very low prevalence of obstructive CAD and adverse events. The proposed strategy may improve risk stratification and help reduce unneeded diagnostic testing.
引用
- Rasmussen, Fordyce, Nissen, et al. The PROMISE Minimal Risk Score Improves Risk Classification of Symptomatic Patients With Suspected CAD. JACC Cardiovasc Imaging. 2022. PMID: 35926903. doi:10.1016/j.jcmg.2022.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。